EvilCorporations.com • Case No. 4:20-CV-10249 | FTC v. ZyCal Bioceuticals • 18 min read

ZyCal Bioceuticals Sold Hope to People in Pain. The Science Didn’t Exist.

For years, ZyCal Bioceuticals Healthcare Company marketed products called Ostinol, Pro-Stiminol, and Chondrinol to people dealing with some of the most painful, life-limiting conditions a body can face: osteoporosis, osteoarthritis, degenerative joint disease. The pitch was that their proprietary ingredient, Cyplexinol, could actually grow new bone and cartilage. The Federal Trade Commission investigated and found that claim had no adequate scientific support. Here is what the court record shows.

The Non-Financial Ledger: What Pain Costs When the Treatment Is a Lie

Think about who buys a product called Ostinol. It is not a college athlete stocking up on protein powder. It is not someone who feels fine and wants to optimize. It is someone who has been told by a doctor that their bones are thinning, that their joints are breaking down, that the body they have lived in for decades is eroding underneath them. It is someone who has maybe tried the prescription routes, worried about side effects, watched the co-pays climb, and started looking for something that felt more natural, more hopeful.

ZyCal found those people. Their marketing language, as documented in the FTC complaint, told them that Cyplexinol was osteoinductive, which means it causes bone tissue to grow. It told them the product could grow cartilage. It told them it could improve bone density and relieve joint pain. These are not mild wellness claims. These are the specific promises that someone with osteoporosis or severe arthritis is most desperate to hear.

The FTC found those promises lacked the required scientific foundation. No randomized, double-blind, placebo-controlled human clinical trials confirmed what ZyCal was selling. The placebo-controlled standard exists precisely because the human body is astonishingly good at feeling better when it expects to. People in pain who believe a treatment is working will frequently report improvement. That is not weakness or stupidity. That is biology. Controlled trials are designed to strip that effect out and reveal whether the treatment itself is doing anything real.

ZyCal sold a product to people who were suffering, charged them real money, and made claims the law says required that clinical standard to make. The damage is not only financial. Consider what happens to trust. Someone with osteoporosis who spends months on a supplement that does not work has spent those months not pursuing something that might. Consider what happens to the relationship between a patient and the evidence. When you believe a product is growing your bones and the pain stays or gets worse, you may blame yourself before you blame the company. You may push harder, buy more, tell yourself you just need to give it time.

Consider what happens to hope itself. People with chronic orthopedic conditions do not have an infinite supply of it. Each treatment that fails takes something. The settlement forces ZyCal to notify customers and stop the claims, but there is no provision in a consent order that gives back the months, the money, or the faith that was spent.

That is the letter ZyCal was ordered to send to its own customers. Read it slowly. The company itself, under court order and on its own letterhead, had to tell the people who trusted it that the government concluded the products it sold them were not scientifically supported. There is no way to read that sentence charitably. The only question left is how many people received that letter and how many did not, because the FTC’s notification requirement only covered direct purchasers from ZyCal’s own websites and from January 2018 onward. Anyone who bought Cyplexinol products through a distributor, a licensee, or a retailer before 2018 received nothing.

Legal Receipts: What the Court Record Actually Says

The following are direct, verbatim quotes from the court document (Case 4:20-cv-10249-TSH Document 84, filed February 6, 2023). Each is followed by a plain-language breakdown of what it proves.

“The Complaint charges that Defendants participated in deceptive acts or practices in violation of Sections 5 and 12 of the FTC Act, 15 U.S.C. §§ 45 and 52, in the marketing and sale of one or more Cyplexinol Products.”

• Section 5 of the FTC Act prohibits unfair or deceptive acts in commerce. Section 12 specifically prohibits false advertisements for food, drugs, and devices. The FTC charged ZyCal under both provisions, meaning regulators concluded the marketing was deceptive and that the products were being advertised with false health claims.
• The phrase “one or more Cyplexinol Products” is significant. The misconduct was not limited to a single product. Ostinol, Pro-Stiminol, and Chondrinol all contain Cyplexinol and all fall under the order’s restrictions.

“[Defendants are permanently restrained and enjoined from making] any representation that such product: A. Grows bone tissue or is osteoinductive; B. Grows cartilage tissue; C. Improves bone density or slows bone loss; D. Cures, treats, or mitigates any orthopedic condition, including osteoarthritis, arthritis, osteoporosis, degenerative joint conditions, joint pain, and pain resulting from inflammation; or E. Cures, mitigates, or treats any disease.”

• This is a permanent ban. Not a temporary restriction. Not a warning. ZyCal and Scaffidi are permanently enjoined from every major claim they were making to sell these products, unless and until they produce the clinical trial evidence they previously lacked.
• The list covers the entire therapeutic pitch: bone growth, cartilage growth, bone density, joint conditions by name, and disease treatment. There is no version of the old marketing that survives this order.

“For purposes of this Section, competent and reliable scientific evidence shall consist of human clinical testing of the Covered Product, or of an Essentially Equivalent Product, that is sufficient in quality and quantity based on standards generally accepted by experts in the relevant disease, condition, or function… Such testing must be: (1) randomized, double-blind, and placebo-controlled; and (2) conducted by researchers qualified by training and experience to conduct such testing.”

• The court is specifying that the bar for making these claims is randomized, double-blind, placebo-controlled human clinical trials. This is the same standard required to approve pharmaceutical drugs. ZyCal was making drug-level health claims without drug-level evidence.
• The burden of proof clause is critical: “Persons covered by this Section have the burden of proving that a product satisfies the definition of Essentially Equivalent Product.” ZyCal cannot coast on someone else’s clinical data for a similar ingredient without proving equivalence. The burden is on them.

“[Defendants are permanently restrained from] misrepresenting… The existence, contents, validity, results, conclusions, or interpretations of any test, study, or other research, including by misreporting the number of study participants and their demographic information or by failing to disclose potential conflicts of interest between the study sponsors or authors and the study participants.”

• The court order specifically calls out misreporting study participant numbers and failing to disclose conflicts of interest between study sponsors and participants. These are not abstract concerns. Regulators wrote this restriction because these specific problems were relevant to ZyCal’s conduct.
• This clause implies ZyCal may have cited studies in its marketing while obscuring who funded those studies or how many people actually participated. That kind of selective presentation is how pseudoscience launders itself as legitimate research.

“We’re writing because you bought Cyplexinol products, such as Ostinol. According to the Federal Trade Commission (FTC), ZyCal doesn’t have scientific evidence to support advertising claims that Cyplexinol grows bone, grows cartilage, or relieves joint pain. To settle the case, ZyCal has agreed to stop making these claims, unless it has adequate scientific evidence.”

(Attachment A: Mandatory customer notice, to be sent on ZyCal letterhead or with ZyCal logo)

• This is the verbatim text of the notice ZyCal was court-ordered to send to customers. The FTC dictated the exact wording and format. ZyCal had to deliver this on its own branded letterhead, which means every recipient saw their trusted supplier admit, in the supplier’s own name, that the government found the claims baseless.
• The notice had to go out within 30 days of the order. ZyCal was also required to resend the email version one to three days later to anyone who did not open the initial message, and to report email open rates, click-to-open rates, and unique click rates to the FTC. The regulator was watching to make sure customers actually received the news.

Societal Impact Mapping: Who Gets Hurt and How

Public Health

The harm from false bone and joint health claims extends beyond individual consumers. It distorts the supplement marketplace in ways that damage public health infrastructure.

• People with documented conditions like osteoporosis, osteoarthritis, and degenerative joint disease, who are often elderly or chronically ill, were the target market. These populations have the least capacity to absorb financial loss and the most to lose from delayed or ineffective treatment.
• The products were sold not only to consumers but also to health professionals, distributors, and licensees. When a doctor or physical therapist recommends a product based on false advertising claims, the deception is laundered through a trusted relationship. Patients have no reason to question a recommendation from a healthcare provider.
• The FTC’s complaint focused on the period from January 2018 forward for the customer notice requirement, but the products containing Cyplexinol existed under names including Ostinol, Pro-Stiminol, and Chondrinol with no documented endpoint on when the deceptive marketing began. Anyone who purchased before 2018 or through non-direct channels received no court-mandated correction.
• Unsubstantiated bone-growth and joint-repair claims in the supplement industry create a broader public health problem: they allow the most medically vulnerable people to defer proven treatments (weight-bearing exercise, bisphosphonate medications for osteoporosis, physical therapy) in favor of supplements that have not been put through clinical scrutiny.
• The specific ban on misrepresenting study participant numbers and conflicts of interest between study sponsors and participants (Section III of the order) signals that regulators found evidence of manipulated or selectively presented research. Corrupted research in the supplement space poisons the information environment that patients and providers use to make decisions.

Economic Inequality

The economic harm from this case falls hardest on people who can least afford to absorb it, and the structure of the supplement industry ensures the financial damage is distributed unequally.

• Older adults on fixed incomes are disproportionately affected by orthopedic conditions. They are also disproportionately represented among supplement buyers, because prescription co-pays are high and supplements are marketed as affordable, natural alternatives. Money spent on Ostinol or Chondrinol was money not spent on rent, food, or legitimate medical care.
• The FTC’s coverage period for the mandatory customer notice starts at January 1, 2018. Purchasers before that date received nothing from the settlement, meaning years of potential sales preceding 2018 carry no remediation at all. The order contains no monetary redress provision for consumers who were harmed.
• Distributors, wholesalers, and licensees who built businesses or product lines around Cyplexinol products faced real economic disruption. Small health retailers who stocked these products in good faith, relying on ZyCal’s marketing materials, now must reckon with the reputational and financial consequences of having sold a product the FTC found to be deceptively marketed.
• The 10-year compliance monitoring regime imposed on ZyCal and Scaffidi costs the government enforcement resources. Those resources are finite. Every case like this one is a case that the FTC has to close while other deceptive supplement marketers continue operating. The supplement industry’s structural lack of pre-market approval requirements for health claims means enforcement is always reactive, always behind, and always incomplete.
• James J. Scaffidi, named personally as an individual defendant, is subject to personal compliance obligations and reporting requirements for 10 years. The order requires him to disclose any change in business structure, ownership, address, or role. However, the order contains no personal financial penalty or monetary judgment visible in the document. Individuals who run deceptive supplement companies typically continue to participate in commerce with minimal personal financial consequence beyond compliance costs.

The “Cost of a Life” Metric: What This Settlement Did Not Deliver

The court order governing this case contains no monetary redress for consumers. There is no fine, no disgorgement of profits, no consumer refund fund visible in the settlement document. The only financial implication for ZyCal is compliance costs: record-keeping, reporting, legal overhead. This metric card represents what that absence means.

What Now: Who to Watch and What to Do

ZyCal Bioceuticals and James J. Scaffidi are under court order. But the structures that allowed this to happen are still intact. Here is who holds accountability, and what you can do about it.

Key Actors (Verified in Source Document)

• ZyCal Bioceuticals Healthcare Company, Inc.: The corporate defendant. Subject to permanent injunction and 10-year compliance reporting. Any future violation of this order is a contempt of federal court.
• James J. Scaffidi: Named individually as an officer of ZyCal. Subject to personal compliance obligations including reporting any new business activity, change of address, and ownership interests for 10 years.

Watchlist: Regulatory Bodies with Jurisdiction

• Federal Trade Commission (FTC): The agency that brought this case. The FTC’s Bureau of Consumer Protection handles dietary supplement advertising fraud. File reports at ftc.gov/complaint. All future ZyCal compliance submissions go to DEbrief@ftc.gov, File No. X200017.
• U.S. Food and Drug Administration (FDA): Has jurisdiction over dietary supplement labeling under the Dietary Supplement Health and Education Act (DSHEA). The court order explicitly preserves FDA authority. If ZyCal’s products appear with unauthorized health claims on labels, that is an FDA enforcement matter.
• U.S. District Court, District of Massachusetts: This court retains jurisdiction over this order. Violations can be brought back to this court as contempt proceedings. Case No. 4:20-CV-10249, Judge T.S. Hillman.
• State Attorneys General: State consumer protection divisions can open parallel investigations when companies engage in deceptive health marketing. If you are in Massachusetts or any state where these products were sold, your AG’s office has standing to act independently.

Action Steps: Mutual Aid and Grassroots Resistance

• Report to the FTC directly: If you purchased Cyplexinol products (Ostinol, Pro-Stiminol, Chondrinol) and did not receive the court-mandated notification letter, file a complaint at ftc.gov/complaint. Your report becomes part of the enforcement record.
• Document what you spent: Save receipts, order confirmation emails, and any marketing materials you received. These documents are relevant to both FTC complaints and any potential state consumer protection actions.
• Share the mandatory notice text: The court-ordered letter (Attachment A) is public record. Share it with anyone who bought these products, especially older family members who may have been targeted by joint health supplement marketing and who may not know this case exists.
• Support supplement industry reform advocacy: The structural problem here is the Dietary Supplement Health and Education Act of 1994, which allows supplements to make structure-function claims without pre-market proof. Organizations advocating for stronger pre-market scientific standards for supplement health claims deserve support. The FTC can only catch cases after the harm is done. Reform requires changing the law.
• Talk to your healthcare provider: If you or someone you care for has been managing osteoporosis, osteoarthritis, or joint disease with supplements instead of or alongside evidence-based treatments, have a direct conversation about what the clinical evidence actually supports. That conversation is the most direct protection against this kind of marketing.